Updates are available Correction dated 2023-12-28
Click to view Correction: https://doi.org/10.1007/s10072-023-07294-7
-
Authors
Bologna, Matteo http://orcid.org/0000-0003-0165-0833
Guerra, Andrea
Colella, Donato
Birreci, Daniele
Costa, Davide
Cannavacciuolo, Antonio
Angelini, Luca
Paparella, Giulia
Antonini, Angelo
Berardelli, Alfredo
Fabbrini, Giovanni
-
Funding
Funding for this research was provided by:
This work was supported by BIAL - Portela & Ca, S.A.
Università degli Studi di Roma La Sapienza
- License Information
-
More Information
Article History
Received: 10 October 2023
Accepted: 27 November 2023
First Online: 13 December 2023
Change Date: 28 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10072-023-07294-7
Declarations
:
: The study received approval from the local Ethics Committee (Sapienza University of Rome). The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. All participants provided informed consent to the experimental procedures and for publication.
: Angelo Antonini has received compensation for consultancy and speaker-related activities from UCB, Britannia, AbbVie, Zambon, Bial, Ever Pharma, Theravance Biopharma, Roche, General Electric, and Medscape. He receives research support from Chiesi Pharmaceuticals, Lundbeck, Bial, Movement Disorder Society, Horizon2020 Grant 825785, Horizon2020 Grant 101016902, and Ministry of Education University and Research (MIUR) Grant ARS01_01081. Matteo Bologna, Andrea Guerra, Donato Colella, Daniele Birreci, Davide Costa, Antonio Cannavacciuolo, Luca Angelini, Giulia Paparella, Alfredo Berardelli, and Giovanni Fabbrini declare that they have no competing interests.
